research funding database


This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

Interventional Research Studies with Elranatamab (multipe myeloma | worldwide)

Share this post

Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange plus symbol appears between the two logos.
Logo of scientifyRESEARCH + logo of Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.

The Interventional Research Studies with Elranatamab research grant from Pfizer supports research on generating evidence on priority gaps in the use of elranatamab in multiple myeloma across lines of treatment, and in particular:

  • Combination with novel agents
  • Frontline use of elranatamab in newly diagnosed multiple myeloma, including sequencing with autologous Stem-Cell Transplant (ASCT)/Chimeric Antigen Receptor T-cells (CAR-T), focus on
    subpopulations of unmet needs, segmentation based on disease biology
  • Optimal administration of elranatamab treatment in patient subpopulations based on patients (e.g. age/fitness/comorbidities), risk (e.g. HRCA, extramedullary disease, high tumor burden) and
    response characteristics ‘
  • Characterization, monitoring, and mitigation strategies of: Infections, CRS, Neurotoxicity/ ICANS, viral reactivation (incl. observing and monitoring emerging infections), other adverse events of
    elranatamab treatment
  • Investigation and intervention of resistance/relapse mechanisms to elranatamab treatment, with focus on strategies to mitigate T-cell exhaustion and its clinical outcomes
  • Retreatment-rechallenging strategies

Applicants may apply for up to 1.5 million USD in funding support (including up to 28% of overheads).

Applications close on July 18, 2024.

The grant has closed Sign-up for our content alerts to be updated when it re-opens.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for the
monthly funding newsletter

unsubscribe at any time